Pembrolizumab showed a manageable toxicity profile and promising antitumor activity.53 The FDA approved pembrolizumab for previously treated patients with recurrent locally advanced or metastatic GC or GEJC whose tumors express PD‐L1. This evidence concerns the gene CD274 and gastric cancer.